Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Multi-hit TP53 mutation is an independent adverse prognostic factor in allogeneic hematopoietic stem cell transplantation for acute leukemia and myelodysplastic syndromes

View Full Paper
Ask AI
Bookmark
Share

Authors

LJLong JingPLPeihua Lu

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows TP53 status impacts prognosis in acute leukemia patients undergoing HSCT, suggesting mutation burden influences outcomes.

Key Points

  • This study assesses the prognostic impact of multi-hit TP53 mutations in patients undergoing allogeneic hematopoietic stem cell transplantation.
  • Retrospective analysis of 272 patients with TP53 mutations who underwent allo-HSCT from 2019 to 2023.
  • Classification of TP53 status per 2022 ICC guidelines and comparison of clinical features between single and multi-TP53 mutations.
  • Outcomes analyzed included overall survival and relapse rates, with follow-up data up to 13.8 months.
  • The single-TP53mut group demonstrated higher 2-year overall survival (62.8%) compared to the multi-TP53mut group (45.5%).
  • Cumulative incidence of relapse was significantly lower in the single-TP53mut group (15.6%) than in the multi-TP53mut group (35.5%).
  • Achieving remission before transplant was associated with better overall survival and lower non-relapse mortality rates.

Cite This Study

Jing et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e51ehttps://doi.org/10.1182/blood-2025-2493
View Full Paper
Ask AI
Bookmark
Share